Efranat Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Out of Business

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Out of Business

Efranat General Information

Description

Developer of an immunotherapy treatment for cancer based in Rehovot, Israel. The company develops an anticancer immunotherapy treatment based on a natural plasma protein molecule, it is based on the concept of engaging the body's immune system and harnessing it against cancer.

Contact Information

Website
www.efranat.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • Prof. Hillel ve-Khanan Oppenheimer 7
  • Rehovot 76701
  • Israel
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Prof. Hillel ve-Khanan Oppenheimer 7
  • Rehovot 76701
  • Israel

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Efranat Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 01-Nov-2018 Completed Out of Business
3. Angel (individual) 30-Apr-2016 Completed Generating Revenue
2. Seed Round 18-Nov-2014 $4.5M $4.5M Completed Startup
1. Angel (individual) 04-Mar-2014 Completed Startup
To view Efranat’s complete valuation and funding history, request access »

Efranat Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

Efranat Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20180078613-A1 Macrophage activating factor for treating benign or precancerous papillomas Inactive 07-Apr-2015
EP-3307300-A1 Macrophage activating factor for treating benign or precancerous papillomas Inactive 07-Apr-2015
US-20160120946-A1 Compositions comprising gc-macrophage activating factor and uses thereof Inactive 09-Jun-2013
AU-2014279627-A1 Compositions comprising gc- macrophage activating factor and uses thereof Inactive 09-Jun-2013
EP-3007720-A1 Compositions comprising gc- macrophage activating factor and uses thereof Inactive 09-Jun-2013 A61K38/19
To view Efranat’s complete patent history, request access »

Efranat Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Efranat FAQs

  • When was Efranat founded?

    Efranat was founded in 2009.

  • Where is Efranat headquartered?

    Efranat is headquartered in Rehovot, Israel.

  • What is the size of Efranat?

    Efranat has 13 total employees.

  • What industry is Efranat in?

    Efranat’s primary industry is Biotechnology.

  • Is Efranat a private or public company?

    Efranat is a Private company.

  • What is Efranat’s current revenue?

    The current revenue for Efranat is .

  • How much funding has Efranat raised over time?

    Efranat has raised $5.3M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »